V(1A) -vasopressin receptors blockade reduces the fluoxetine-induced pressor response in freely moving rats;Reduction de l'effet presseur de la fluoxetine apres blocage des recepteurs V(1A) de la vasopressine, chez le rat conscient

Archives des Maladies du Coeur et des Vaisseaux

Volumn 92, Issue 8, 1999, Pages 985-989

  Lazartigues, E ^a   Costes, S ^a   Brefel Courbon, C ^a   Gharib, C ^b   Tran, M A ^a   Senard, J M ^a   Montastruc, J L ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE; KETANSERIN; PRAZOSIN; PROPRANOLOL; SEROTONIN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; HEART RATE; MOVEMENT (PHYSIOLOGY); NONHUMAN; PRESSOR RESPONSE; RAT; SYMPATHETIC TONE; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD PRESSURE; DRUG ANTAGONISM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; FLUOXETINE; INJECTIONS, INTRAVENTRICULAR; MALE; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0033174870     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Pilowsky P, Minson J, Arnolda L et al. Brain serotonin and hypertension. In : Larough, J, Brenner B (eds). Hypertension: Pathophysiology, diagnosis, and management. New York : Raven Press Ltd, 1995 : 775-87.
2. Montastruc JL, Pelat M, Verwaerde P et al. Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study. Fundam Clin Pharmacol 1998 ; 12 : 398-402.
3. Gillman P. Serotonin syndrome: hystory and risk. Fund Clin Pharmacol 1998 ; 12 : 482-91.
4. Brefel C, Lazartigues E, Tran MA et al. Central cardiovascular effects of acetylcholine in the conscious dog. Br J Pharmacol 1995 ; 116 : 2175-82.
5. Steinberg M, Smallwood J, Holland D et al. Hemodynamic and electrocardiographic effects of fluoxetine and its major metabolite, norfluoxetine, in anesthetized dogs. Toxicol Appl Pharmacol 1986 ; 82 : 70-9.
6. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985 ; 46 : 42-4.
7. Gardier A, Jacquot C et Artigas F. Bases neurobiologiques du rôle des récepteurs 5-HT1A dans le mode d'action des antidépresseurs sérotoninergiques. Med Sci 1995 ; 11 : 1407-17.
8. Benfield P, Heel R et Lewis S. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986 ; 32 : 481-508.
9. Bouman W, Pinner G et Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry 1998 ; 13 : 12-5.